Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy Exposure Clear all
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional

Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy

NCT00121888
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Prolonged Exposure Therapy, Paroxetine-CR
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

NCT00064220
View directory record Official record
Conditions
Sarcoma
Interventions
soblidotin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 7, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307
View directory record Official record
Conditions
Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
Interventions
Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

NCT00000922
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 7, 2026, 5:28 AM EDT
Completed No phase listed Observational

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

NCT05803200
View directory record Official record
Conditions
Exposure During Pregnancy
Interventions
No intervention
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 44 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Sep 7, 2026, 5:28 AM EDT
Not listed Phase 2 Interventional

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

NCT00016900
View directory record Official record
Conditions
Esophageal Cancer
Interventions
liposomal paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 7, 2026, 5:28 AM EDT
Completed No phase listed Observational

Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

NCT01982591
View directory record Official record
Conditions
Male Breast Cancer, Neurotoxicity, Peripheral Neuropathy, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Paoli, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 7, 2026, 5:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614
View directory record Official record
Conditions
Nonmuscle-invasive Bladder Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 7, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

NCT04729387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

NCT02569723
View directory record Official record
Conditions
Colon Adenocarcinoma
Interventions
Carbon C 14 Oxaliplatin, Oxaliplatin
Drug
Lead sponsor
Edward Kim
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 7, 2026, 5:28 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

NCT04961190
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Menlo Park, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

NAS Treatment - Opiate Versus Non-Opiate

NCT01734551
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Morphine, Clonidine
Drug
Lead sponsor
Henrietta Bada
Other
Eligibility
1 Day to 7 Days
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 7, 2026, 5:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986
View directory record Official record
Conditions
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions
AMO959, AAA617, Enzalutamide, Abiraterone
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Los Angeles, California • El Paso, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil

NCT02822573
View directory record Official record
Conditions
Cognitive Dysfunction, Memory Impairment
Interventions
Donepezil 5 mg, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
278
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 206 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Sequenced Treatment Effectiveness for Posttraumatic Stress

NCT04597190
View directory record Official record
Conditions
PTSD
Interventions
Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
Drug · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
North Little Rock, Arkansas • West Memphis, Arkansas • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 7, 2026, 5:28 AM EDT
Completed Not applicable Interventional

Systematic Light Exposure for Fatigue in Breast Cancer Patients

NCT03217201
View directory record Official record
Conditions
Cancer-related Problem/Condition, Fatigue, Circadian Rhythm Disorders
Interventions
Light Glasses (Experimental), Light Glasses (Comparison)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 7, 2026, 5:28 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses

NCT06919653
View directory record Official record
Conditions
Chemotherapy Exposure, Handling Guidelines, Oncology Nurse, Adherence
Interventions
The Workplace program to Improve the Safe Handling of hazardous drugs (WISH)
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Vedolizumab Pregnancy Exposure Registry

NCT02678052
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab, Other Biological Agent
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 7, 2026, 5:28 AM EDT